Despite overall progress, the five-year survival rate for patients with non-small cell lung cancer remains 16%. Technological advances have improved our understanding of non-small cell lung cancer biology, allowing the identification of molecular alterations responsible for the growth of the disease itself.

At present, non-small cell lung cancer is considered to be a complex of rare diseases, classified based on the molecular alterations present, some of which are targets of highly effective specific biological drugs.

Through NGS, being an innovative molecular biology method, the sequences of several genes can be analyzed simultaneously. Therefore, the purpose of the study is to validate the ACC oncochip in new cases of patients with non-small, locally advanced or metastatic lung cancer. The goal is to improve the performance of molecular diagnostics in IRCCS to offer patients better therapeutic opportunities.